Why Abzena?
Our focused approach.
Time: 11:10 AM
This exclusive event brings together industry leaders for high-level discussions on the latest advancements in antibody therapeutics. Designed for biotech and pharma executives, it provides a collaborative space to explore innovative solutions shaping the future of drug development.
Antibody-drug conjugates (ADCs) rely on stable linkers to maintain efficacy and safety. In this roundtable, Stephen Verespy, and Kevin Ranke, Directors & Scientific Leaders, will lead a discussion on overcoming linker stability challenges to optimize ADC performance. Engage with fellow experts as we explore innovative solutions shaping the future of ADC development.
Register for the event here: San Diego Antibody Therapeutics Xchange